Suvorexant ameliorated sleep disturbance, opioid withdrawal, and craving during a buprenorphine taper.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Suvorexant ameliorated sleep disturbance, opioid withdrawal, and craving during a buprenorphine taper.
- Published In:
- Science translational medicine, 14(650), eabn8238 (2022)
- Authors:
- Huhn, Andrew S, Finan, Patrick H, Gamaldo, Charlene E, Hammond, Alexis S, Umbricht, Annie, Bergeria, Cecilia L, Strain, Eric C, Dunn, Kelly E
- Database ID:
- RPEP-06210
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-06210APA
Huhn, Andrew S; Finan, Patrick H; Gamaldo, Charlene E; Hammond, Alexis S; Umbricht, Annie; Bergeria, Cecilia L; Strain, Eric C; Dunn, Kelly E. (2022). Suvorexant ameliorated sleep disturbance, opioid withdrawal, and craving during a buprenorphine taper.. Science translational medicine, 14(650), eabn8238. https://doi.org/10.1126/scitranslmed.abn8238
MLA
Huhn, Andrew S, et al. "Suvorexant ameliorated sleep disturbance, opioid withdrawal, and craving during a buprenorphine taper.." Science translational medicine, 2022. https://doi.org/10.1126/scitranslmed.abn8238
RethinkPeptides
RethinkPeptides Research Database. "Suvorexant ameliorated sleep disturbance, opioid withdrawal,..." RPEP-06210. Retrieved from https://rethinkpeptides.com/research/huhn-2022-suvorexant-ameliorated-sleep-disturbance
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.